Navigation Links
Lilly Reports First-Quarter 2011 Results

$1.13(16)%In-process research and development charges

  associated with Boehringer Ingelheim

  collaboration (2011) and Acrux licensing

  agreement (2010).23.03Asset impairments and restructuring charges

.06.02Earnings per share (non-GAAP)  $1.24$1.185%U.S. Health Care Reform Impact

U.S. health care reform reduced first-quarters 2011 and 2010 earnings per share by approximately $.10 and $.12 per share, respectively, on both a reported and non-GAAP basis. For the first quarter of 2011, U.S. health care reform reduced revenue by approximately $90 million due to higher rebates and subsidies, and increased administrative expenses by approximately $45 million related to the mandatory pharmaceutical manufacturers fee. For the first quarter of 2010, U.S. health care reform reduced revenue by approximately $60 million due to higher rebates, and increased tax expense by $85.1 million due to the imposition of tax on the prescription drug subsidy of the company's retiree health plan.(Dollars in millions)First Quarter

% Change












138.7146.4(5)%Animal Health

369.8289.628%Total Revenue


In the first quarter of 2011, Zyprexa sales totaled $1.282 billion, an increase of 6 percent compared with the first quarter of 2010.  U.S. sales of Zyprexa increased 2 percent to $597.1 million, driven by higher prices, partially offset by lower volume. Zyprexa sales in international markets increased 8 percent, to $684.8 million, driven primarily by higher volume, and to a lesser extent the favorable impact of foreign exchang

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
(Date:1/23/2015)... 23, 2015 Gem Pharmaceuticals announced today that the ... into the Company,s Phase 2 clinical trial.  This open-label ... lead compound, GPX-150 (an investigational medication), in approximately 30 ... Logo - ...
(Date:1/23/2015)... China , Jan. 23, 2015 Tianyin Pharmaceutical ... company that specializes in the development and sale of ... generics and active pharmaceutical ingredients (API) today announced the ... (JCM) API operation. 1. Following the September ...
(Date:1/22/2015)... , Jan. 22, 2015  BiOptix is pleased to ... as Vice President of Chemistry and Biochemistry. Scott joins the ... AstraZeneca Pharmaceuticals, and Amgen throughout the course of his ... "Scott is a nationally recognized thought leader ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
(Date:1/22/2015)... City, Florida (PRWEB) January 22, 2015 IsoComforter, ... cold therapy machine with patented IsoTube design to treat specific ... has introduced the most progressive and easy to use patented ... treat post-operative and sports related orthopedic and muscle injuries. ...
(Date:1/22/2015)... 22, 2015 Payday lending practices in ... and cause financial distress to the states that permit ... Howard University’s Center on Race and Wealth. , While ... activity, payday loans at the same time substantially depress ...
(Date:1/22/2015)... January 22, 2015 As interest in the ... care gains momentum worldwide, Rev. Eric J. Hall , ... Network (HCCN), will be the keynote speaker on January ... Israel’s public health system. , The conference, “Hope and Resilience: ...
(Date:1/22/2015)... has released a new blog post presenting a list of vehicles ... , Some types of vehicles cannot be covered under an ... post to see if their vehicle qualifies for auto insurance coverage. ... the cars that cannot be covered by a plan. Clients have ...
(Date:1/22/2015)... January 22, 2015 Step into a ... the Science Museum of Virginia. Wicked Plants, the Museum’s ... Plants unearths 75 poisonous, carnivorous and diabolical plants inside ... room to uncover the biochemical, physical and neurological processes ...
Breaking Medicine News(10 mins):Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2
... HealthDay Reporter , WEDNESDAY, April 11 (HealthDay News) -- ... of the postoperative experience of four children who all carried ... to three of the patients, while a similar case came ... genetic cases, the common painkiller codeine can be lethal. The ...
... published article in the journal Nursing for Women,s Health ... her childbearing. The author asserts that contraception is a means ... care providers to ensure they are healthy prior to conceiving ... According to the Centers for Disease Control and Prevention ...
... Regular walking can help reduce fatigue in some pancreatic cancer ... white men and women aged 66 or 67 who underwent ... before they were discharged from the hospital. One group ... a walking or exercise routine. The other group was told ...
... By Steven Reinberg HealthDay Reporter , TUESDAY, April ... birth controls pills containing drospirenone -- a man-made version of ... risk of blood clots and will require new labels. ... will inform users that the pills -- which include products ...
... April 11, 2012. Anna M. Barrett, MD will represent ... American Academy of Neurology Conference at the Ernest N. ... April 28. Four abstracts will be presented ... of spatial neglect after right-brain stroke. Spatial neglect is ...
... that women are less likely than men to get at ... odds of developing metabolic syndrome a risky and increasingly ... name for a group of risk factors including high ... part of the body which occur together and increase ...
Cached Medicine News:Health News:Codeine After Surgery Could Endanger Certain Kids: Study 2Health News:Codeine After Surgery Could Endanger Certain Kids: Study 3Health News:Codeine After Surgery Could Endanger Certain Kids: Study 4Health News:Timing pregnancy an important health concern for women 2Health News:Short Walks May Ease Fatigue in Pancreatic Cancer Patients 2Health News:Certain Birth Control Pills May Carry Higher Blood Clot Risk: FDA 2Health News:NJ stroke researchers report advances in spatial neglect research at AAN Conference 2Health News:Study: Women not getting enough exercise; at risk of developing metabolic syndrome 2
... performance, the SZX7 is designed for ease ... task, from routine preparations to advanced research. ... zoom ratios in its class as well ... accurate reproduction of the original specimen in ...
The Stereomicroscope Stemi 2000 meets your demands in two respects. On the one hand it offers the low-price advantage common with Greenough-type instruments, on the other hand it features superior pe...
6.3X Zoom Ratio - Boasting magnifications from 0.8X to 5X, the twin zooming objective optical system developed exclusively by Nikon provides a zoom ratio of 6.3:1. Clickstops at 1X intervals allow ob...
Medicine Products: